Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -223.90% is in line with its 5-year average of -206.54%, near the high end of its 5-year range (-1831.18%–-66.41%).
As of the fiscal period ended Tuesday, June 30, 2026. 59.84% above its 12-month average of -557.58%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -223.90%.
RETURN ON INVESTED CAPITAL (ROIC)
-223.90%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-557.58%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-561.26%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-206.54%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+59.84%
CURRENT VS 3Y AVG
+60.11%
CURRENT VS 5Y AVG
-8.41%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-34.77%
median of 761 covered companies
CURRENT VS SECTOR MEDIAN
-543.95%
vs the sector median at left
NervGen Pharma Corp. Common stock
Market Cap
$149.18M
Return on Invested Capital (ROIC)
-223.90%
TTM Avg
-557.58%
3Y Avg
-561.26%
5Y Avg
-206.54%
Market Cap
$148.31M
Return on Invested Capital (ROIC)
-143.97%
TTM Avg
-52.39%
3Y Avg
-55.03%
5Y Avg
-91.26%
Market Cap
$146.88M
Return on Invested Capital (ROIC)
-27.25%
TTM Avg
-49.08%
3Y Avg
-43.31%
5Y Avg
-52.54%
Market Cap
$146.98M
Return on Invested Capital (ROIC)
-118.67%
TTM Avg
-87.91%
3Y Avg
-55.09%
5Y Avg
-41.64%
Market Cap
$151.65M
Return on Invested Capital (ROIC)
-23.41%
TTM Avg
-38.99%
3Y Avg
-40.72%
5Y Avg
-30.95%
Market Cap
$151.58M
Return on Invested Capital (ROIC)
-165.56%
TTM Avg
-176.54%
3Y Avg
-127.81%
5Y Avg
-112.12%
Market Cap
$152.73M
Return on Invested Capital (ROIC)
-56.53%
TTM Avg
-185.89%
3Y Avg
-125.01%
5Y Avg
-88.85%
Market Cap
$144.19M
Return on Invested Capital (ROIC)
-134.15%
TTM Avg
-47.87%
3Y Avg
-96.96%
5Y Avg
-96.99%
Market Cap
$144.10M
Return on Invested Capital (ROIC)
-61.13%
TTM Avg
-65.92%
3Y Avg
-49.38%
5Y Avg
-37.06%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NervGen Pharma Corp. Common stock (NGEN) | $149.18M | -223.90% | -557.58% | -561.26% | -206.54% |
| LifeMD, Inc. (LFMDP)vs › | $148.31M | -143.97% | -52.39% | -55.03% | -91.26% |
| Anavex Life Sciences Corp. (AVXL)vs › | $146.88M | -27.25% | -49.08% | -43.31% | -52.54% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.98M | -118.67% | -87.91% | -55.09% | -41.64% |
| Codexis, Inc. (CDXS)vs › | $151.65M | -23.41% | -38.99% | -40.72% | -30.95% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.58M | -165.56% | -176.54% | -127.81% | -112.12% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $152.73M | -56.53% | -185.89% | -125.01% | -88.85% |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.19M | -134.15% | -47.87% | -96.96% | -96.99% |
| Nyxoah S.A. (NYXH)vs › | $144.10M | -61.13% | -65.92% | -49.38% | -37.06% |
| Immuneering Corporation (IMRX)vs › | $142.31M | -32.73% | -84.24% | -68.85% | -57.28% |
ROIC
-223.9%
ROE
-397.4%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -223.90% |
| 2026-03-31 | -583.73% |
| 2025-12-31 | -865.11% |
| 2025-03-31 | -1831.18% |
| 2024-12-31 | -973.11% |
| 2024-09-30 | -248.68% |
| 2024-06-30 | -154.25% |
| 2024-03-31 | -95.64% |
| 2023-09-30 | -372.29% |
| 2023-06-30 | -264.72% |
| 2023-03-31 | -225.00% |
| 2022-12-31 | -172.93% |
| 2022-09-30 | -112.11% |
| 2022-06-30 | -174.13% |
| 2022-03-31 | -109.03% |
| 2021-12-31 | -66.41% |
| 2021-09-30 | -149.62% |
| 2021-06-30 | -145.61% |
| 2021-03-31 | -209.49% |
| 2020-12-31 | -174.50% |
| 2020-09-30 | -93.68% |
| 2020-06-30 | -176.02% |
| 2020-03-31 | -199.20% |
| 2019-12-31 | -163.68% |
| 2019-09-30 | -118.78% |
| 2019-06-30 | -67.13% |
| 2019-03-31 | -47.11% |
| 2018-12-31 | -52.79% |
| 2018-09-30 | -17.62% |
